Innate Pharma Stock Net Income
| IPHYF Stock | USD 2.15 0.00 0.00% |
As of the 17th of February 2026, Innate Pharma retains the Market Risk Adjusted Performance of (0.72), standard deviation of 1.63, and Risk Adjusted Performance of 0.0653. Innate Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Innate Pharma variance and kurtosis to decide if Innate Pharma is priced fairly, providing market reflects its last-minute price of 2.15 per share. Please also validate Innate Pharma information ratio, which is currently at 0.0318 to confirm the company can sustain itself at a future point.
Innate Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Innate Pharma's valuation are provided below:Innate Pharma does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Innate |
Innate Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Innate Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Innate Pharma.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Innate Pharma on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Innate Pharma or generate 0.0% return on investment in Innate Pharma over 90 days. Innate Pharma is related to or competes with NDT Pharmaceuticals, Molecular Partners, Scancell Holdings, Brii Biosciences, Ascend Wellness, JW (Cayman), and Hofseth BioCare. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the trea... More
Innate Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Innate Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Innate Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0318 | |||
| Maximum Drawdown | 12.57 |
Innate Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Innate Pharma's standard deviation. In reality, there are many statistical measures that can use Innate Pharma historical prices to predict the future Innate Pharma's volatility.| Risk Adjusted Performance | 0.0653 | |||
| Jensen Alpha | 0.121 | |||
| Total Risk Alpha | (0.01) | |||
| Treynor Ratio | (0.73) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Innate Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Innate Pharma February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0653 | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 0.3771 | |||
| Coefficient Of Variation | 1339.58 | |||
| Standard Deviation | 1.63 | |||
| Variance | 2.67 | |||
| Information Ratio | 0.0318 | |||
| Jensen Alpha | 0.121 | |||
| Total Risk Alpha | (0.01) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 12.57 | |||
| Skewness | 6.76 | |||
| Kurtosis | 54.45 |
Innate Pharma Backtested Returns
At this point, Innate Pharma is relatively risky. Innate Pharma holds Efficiency (Sharpe) Ratio of 0.0783, which attests that the entity had a 0.0783 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Innate Pharma, which you can use to evaluate the volatility of the firm. Please check out Innate Pharma's Market Risk Adjusted Performance of (0.72), risk adjusted performance of 0.0653, and Standard Deviation of 1.63 to validate if the risk estimate we provide is consistent with the expected return of 0.13%. Innate Pharma has a performance score of 6 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.15, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Innate Pharma are expected to decrease at a much lower rate. During the bear market, Innate Pharma is likely to outperform the market. Innate Pharma right now retains a risk of 1.71%. Please check out Innate Pharma variance and kurtosis , to decide if Innate Pharma will be following its current trending patterns.
Auto-correlation | 0.00 |
No correlation between past and present
Innate Pharma has no correlation between past and present. Overlapping area represents the amount of predictability between Innate Pharma time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Innate Pharma price movement. The serial correlation of 0.0 indicates that just 0.0% of current Innate Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Innate Pharma reported net income of (52.81 Million). This is 115.47% lower than that of the Healthcare sector and 175.39% lower than that of the Biotechnology industry. The net income for all United States stocks is 109.25% higher than that of the company.
Innate Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in net income category among its peers.
Innate Fundamentals
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 91.32 M | |||
| Shares Outstanding | 80.21 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 40.00 X | |||
| Price To Book | 1.48 X | |||
| Price To Sales | 3.27 X | |||
| Revenue | 12.11 M | |||
| Gross Profit | (22.3 M) | |||
| EBITDA | (36.88 M) | |||
| Net Income | (52.81 M) | |||
| Cash And Equivalents | 123.35 M | |||
| Cash Per Share | 1.54 X | |||
| Total Debt | 13.5 M | |||
| Debt To Equity | 0.37 % | |||
| Current Ratio | 2.34 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (58.46 M) | |||
| Earnings Per Share | (0.69) X | |||
| Number Of Employees | 213 | |||
| Beta | 0.33 | |||
| Market Capitalization | 275.93 M | |||
| Total Asset | 267.5 M | |||
| Z Score | 12.0 | |||
| Net Asset | 267.5 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Additional Information and Resources on Investing in Innate Pink Sheet
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Innate Pink Sheet please use our How to Invest in Innate Pharma guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.